

Tirzepatide Prescription Order Form

Patient Name: _____ Date of Birth: _____ Date: _____ Phone: _____ Email: _____
Address: _____ City: _____ State: _____ Zip: _____ Allergy: _____ Diagnosis: _____ License/ID: _____

This Compounded Medication is Medically Necessary <i>Select one</i>	Quantity	Instructions
	<i>Select one</i>	<i>Select one</i>
<input type="checkbox"/> <u>Tirzepatide/Cyanocobalamin (B12)</u> 12.5mg—0.5mg/mL	<input type="checkbox"/> 1 Vial	<input type="checkbox"/> 2.5mg – Inject 20 units (0.2mL) subcutaneously weekly for 4 weeks (5mL vial) <input type="checkbox"/> 5mg – Inject 40 units (0.4mL) subcutaneously weekly for 4 weeks (5mL vial) <input type="checkbox"/> 7.5mg – Inject 60 units (0.6mL) subcutaneously weekly for 4 weeks (5mL vial) <input type="checkbox"/> 10mg – Inject 80 units (0.8mL) subcutaneously weekly for 4 weeks (5mL vial) <input type="checkbox"/> 12.5mg – Inject 100 units (1mL) subcutaneously weekly for 4 weeks (5mL vial) <input type="checkbox"/> ____ mg – Inject ____ units subcutaneously weekly for 4 weeks (5mL vial)
<input type="checkbox"/> <u>Tirzepatide/Pyridoxine (B6)</u> 12.5mg—50mg/mL	<input type="checkbox"/> 2 Vials	
<input type="checkbox"/> <u>Tirzepatide/Leucine/Isoleucine/Valine</u> 12.5mg—10mg—10mg—10mg/mL	<input type="checkbox"/> 3 Vials	

Dr. Name (Print) _____ Signature _____ License _____

NPI # _____ Phone Number _____ Fax Number _____ Email _____

Address _____ City _____ State _____ Zip _____

With the recent resolution of the tirzepatide shortage, we will no longer compound commercially available tirzepatide products. However, we will continue to provide a **custom compounded tirzepatide formulation** only for patients with **specific medical needs** that cannot be addressed with the commercial product. These may include, but are not limited to:

Intolerance to rapid titration due to severe gastrointestinal effects (e.g., nausea, vomiting)
 Fatigue or metabolic insufficiency
 Unintended muscle loss

Need for alternative strengths, delivery systems, or inactive ingredient profiles
 Other _____

By signing this prescription, you acknowledge that:

The patient has a documented clinical need for a compounded version of tirzepatide

The commercial product is **not appropriate or sufficient** for this patient

You are requesting this compounded medication as a **personalized therapy** under your professional judgment

⚠ This compounded preparation is provided under Section 503A of the Federal Food, Drug, and Cosmetic Act. It is not FDA-approved and is dispensed only with a valid patient-specific prescription.

This document contains HIPAA-protected health information.